/ /

  • linkedin
  • Increase Font
  • Sharebar

    ‘Real-world’ ocriplasmin macular hole closure rates lag trials


    “Grouped together, these observations indicate ocriplasmin has a more widespread action than the target vitreoretinal interface, and are suggestive of enzyme action both within the retina and the sub-retinal space, rather than just at the target vitreoretinal interface,” Haynes and colleagues wrote.

    The rates of several categories of adverse event reported by the BEAVRS physicians were higher than in the MIVI TRUST, though the researchers did not report statistical significance. For example, the BEAVRS rate of retinal detachment was 3.3% compared to 0.4% in the MIVI TRUST. One contributing factor could be the exclusion of patients with high myopia from the MIVI TRUST trials, the researchers speculated.

    Another possible explanation for the difference in results between the studies could be negative reporting bias; perhaps BEAVRS physicians were more likely to report results if they were disappointed, Haynes and colleagues suggested.

    As alternative explanations, they also suggested there could be differences in technique among the physicians in the two studies, or differences in the populations.


    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results